Targeted Therapy of Myelofibrosis

Background. Myelofibrosis (primary myelofibrosis, post-essential trombocythemia myelofibrosis, post-polycythemia myelofibrosis) is the most complex and pressing problem among all Ph-negative myeloproliferative diseases. The present article summarizes the author’s experience of using new Janus kinase...

Full description

Bibliographic Details
Published in:Клиническая онкогематология
Main Authors: OYu Vinogradova, VA Shuvaev, IS Martynkevich, MM Pankrashkina, MS Fominykh, EV Efremova, KYu Krutikova, LB Polushkina, NN Sharkunov, SV Voloshin, AV Chechetkin
Format: Article
Language:Russian
Published: Practical Medicine Publishing House 2017-10-01
Subjects:
primary myelofibrosis
post-essential trombocythemia myelofibrosis
post-polycythemia myelofibrosis
JAK2V617F
ruxolitinib
clinical practice
targeted therapy
Online Access:http://bloodjournal.ru/wp-content/uploads/2017/10/6_1.pdf

Internet

http://bloodjournal.ru/wp-content/uploads/2017/10/6_1.pdf

Similar Items